Finance

Lists
IBAB:EBR
Ion Beam Applications SA
€15.22
-0.26%
(-0.040) 1D
Sep 18, 4:13:50 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for IBAB...
Open
€15.24
High
€15.38
Low
€15.18
Mkt. cap
460.90M
Avg. vol.
20.68K
Volume
6.11K
Dividend
1.15%
Quarterly dividend
€0.04
Ex-dividend date
Jun 15, 2026
P/E ratio
19.12
52-wk high
€17.76
52-wk low
€9.90
EPS
€0.80
Shares outstanding
30.28M
No. of employees
2K
Open
€15.24
High
€15.38
Low
€15.18
Mkt. cap
460.90M
Avg. vol.
20.68K
Volume
6.11K
Dividend
1.15%
Quarterly dividend
€0.04
Ex-dividend date
Jun 15, 2026
P/E ratio
19.12
52-wk high
€17.76
52-wk low
€9.90
EPS
€0.80
Shares outstanding
30.28M
No. of employees
2K
Profile
IBA is a medical technology company based in Louvain-la-Neuve. The company was founded in 1986 by Yves Jongen within the Cyclotron Research Center of the University of Louvain and became a university spin-off. It employs about 1500 people in 40 locations. The company developed cyclotrons and integrated proton therapy centers is active in the field of proton therapy, dosimetry, radiopharmacy solutions and industrial sterilisation. IBA installed its first proton therapy equipment for Boston's Massachusetts General Hospital in 2001, and for University of Pennsylvania's Proton Center in 2009. It supplied equipment and services to Proton Partners International which was developing three proton beam therapy centers in the United Kingdom. In 2017, IBA invested €16 million in the construction of a new logistics and production center in Louvain-la-Neuve. Wikipedia
About Ion Beam Applications SA
CEOOlivier Legrain
Employees2.26K
Founded1986
Headquarters-
SectorMedical device
Websiteiba-worldwide.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
157.64M
157.64M
161.87M
161.87M
Cost of goods sold
102.83M
102.83M
107.40M
107.40M
Cost of revenue
102.83M
102.83M
107.40M
107.40M
Research and development expenses
15.48M
15.48M
18.20M
18.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
30.94M
30.94M
28.22M
28.22M
Operating expense
40.94M
40.94M
48.03M
48.03M
Total operating expenses
143.77M
143.77M
155.43M
155.43M
Operating income
13.86M
13.86M
6.45M
6.45M
Other non operating income
-1.29M
-1.29M
-
-
EBT including unusual items
8.78M
8.78M
6.14M
6.14M
EBT excluding unusual items
13.05M
13.05M
6.20M
6.20M
Income tax expense
1.12M
1.12M
1.48M
1.48M
Effective tax rate
12.73%
12.73%
24.10%
24.10%
Other operating expenses
-5.83M
-5.83M
1.60M
1.60M
Net income
7.67M
7.67M
4.66M
4.66M
Net profit margin
4.86%
4.86%
2.88%
2.88%
Earnings per share
-
-
-
-
Interest and investment income
2.13M
2.13M
1.88M
1.88M
Interest expense
-
-
-3.18M
-3.18M
Net interest expenses
2.13M
2.13M
-1.31M
-1.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
15.80M
15.17M
8.41M
8.41M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps